Clinical experience of docetaxel and epirubicin based neoadjuvant chemotherapy for locally advanced breast cancer
WANG Yajing1, LIU Dequan2, , YE Jianqiao3
1. Graduate Institute, Kunming Medical University, Kunming 650031, China; 2. Department of Breast Surgery, Yunnan Cancer Hospital, Kunming 650106, China; 3. Department of General Surgery, General Hospital of Shenyang Military Region of PLA, Shenyang 110016, China
Abstract：Objective To assess the response rates (clinical and pathological) with docetaxel and epirubicin combination chemotherapy and its effect on outcome. Methods Locally advanced breast cancer (LABC) patients who received NACT from January 2009 to December 2012 in this hospital were retrospectively analysed. Some information of the patients was collected including basic information, clinical stages and the situation of estrogen receptor and progesterone receptor. The regimens used for NACT consisted of six cycles of DEC (docetaxel 75 mg/m2, epirubicin 75 mg/m2, cyclophosphamide 500 mg/m2 on day 1, 3 weekly) and a sequential regimen (4 cycles of FEC, 5-flurouracil 600 mg/m2, epirubicin 75 mg/m2, cyclophosphamide 600 mg/m2 followed by 4 cycles of docetaxel 85 mg/m2). Clinical response and pathological response rates, time of relapse and 3 year survival rate were assessed. Results The median age was 46 years. Ninety-six patrents (80%) had T4 disease and 90% had clinically palpable lymph nodes at diagnosis. The median size of primary tumor at presentation was 5.9 cm. Hormone receptor positivity was seen in 55% of patients and HER2/neu positivity in 25%. Triple negative breast cancers constituted of 25% of the patients. Totally 100 cases showed clinical response, accounting for 83%; 15 cases showed clinical stability; 5 cased showed clinical progress. 18 cases showed pathological response. There were no significant differences between the two groups in the above data. The median duration of follow-up was 22 months. The median time to relapse was 20 months; 3 year relapse free and overall survival rates were 50% and 70%, respectively. The differences between the two groups was not statically significant. Conclusions LABC patients have good outcome after neoadjuvant chemotherapy. Sequential chemotherapy is well tolerated than concurrent docetaxel and epirubicin chemotherapy with a similar PCR(pathological complete response).
王雅婧,刘德权,叶剑桥. 多西他赛与表柔比星联合或序贯化疗治疗局部晚期乳腺癌临床观察[J]. 武警医学, 2014, 25(9): 921-923.
WANG Yajing, LIU Dequan, , YE Jianqiao. Clinical experience of docetaxel and epirubicin based neoadjuvant chemotherapy for locally advanced breast cancer. Med. J. Chin. Peop. Armed Poli. Forc., 2014, 25(9): 921-923.
Mathew J, Asgeirsson K S, Agrawal A, et al. Neoadjuvant chemotherapy in locally advanced primary breast cancers: the Nottingham experience [J]. Eur J Surg Oncol, 2007, 33(8): 972-976.
Rastogi P, Anderson S J, Bear H D, et al. Preoperative chemo-therapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27 [J]. J Clin Oncol, 2008, 26(16): 778-785.
[2]
Mathew J, Asgeirsson K S, Agrawal A, et al. Neoadjuvant chemotherapy in locally advanced primary breast cancers: the Nottingham experience [J]. Eur J Surg Oncol, 2007, 33(8): 972-976.
[4]
Gupta D, Raina V, Rath G K, et al. Clinical and pathological response rates of docetaxel-based neoadjuvant chemotherapyin locally advanced breast cancer and comparison with anthracycline-based chemotherapies: eight-year experience from single centre [J]. Indian J Cancer, 2011, 48(4): 410-414.
[3]
Rastogi P, Anderson S J, Bear H D, et al. Preoperative chemo-therapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27 [J]. J Clin Oncol, 2008, 26(16): 778-785.
[5]
Von Minckwitz G, Kummel S, Vogel P, et al. Intensified neo-adjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study [J]. J Natl Cancer Inst, 2008, 100(8): 552-562.
[4]
Gupta D, Raina V, Rath G K, et al. Clinical and pathological response rates of docetaxel-based neoadjuvant chemotherapyin locally advanced breast cancer and comparison with anthracycline-based chemotherapies: eight-year experience from single centre [J]. Indian J Cancer, 2011, 48(4): 410-414.
[6]
Phua C E, Bustam A Z, Yusof M M, et al. Risk of treatment related death and febrile neutropaenia with taxane-based adjuvant chemotherapy for breast cancer in a middle income country outside a clinical trial setting [J]. Asian Pac J Cancer Prev, 2012, 13(9): 4623-4626.
[5]
Von Minckwitz G, Kummel S, Vogel P, et al. Intensified neo-adjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study [J]. J Natl Cancer Inst, 2008, 100(8): 552-562.
[7]
Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort [J]. Lancet, 2010, 375(9712):377-384.
[6]
Phua C E, Bustam A Z, Yusof M M, et al. Risk of treatment related death and febrile neutropaenia with taxane-based adjuvant chemotherapy for breast cancer in a middle income country outside a clinical trial setting [J]. Asian Pac J Cancer Prev, 2012, 13(9): 4623-4626.
[7]
Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort [J]. Lancet, 2010, 375(9712):377-384.
2014, Vol. 25 
